COVID-19 and the liver:Are footprints still there?  

作　　者：Tarana Gupta Hemant Sharma 

机构地区：[1]Department of Medicine,Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences,Rohtak 124001,Haryana,India

出　　处：《World Journal of Gastroenterology》2023年第4期656-669,共14页世界胃肠病学杂志（英文版）

摘　　要：The coronavirus disease 2019(COVID-19)hit the entire world as a global pandemic and soon became the most important concern for all patients with chronic diseases.An early trend in higher mortality in patients with acute respiratory distress attracted all researchers to closely monitor patients for the involvement of other systems.It soon became apparent that patients with chronic liver diseases are at increased risk of mortality given their cirrhosis-associated immune dysfunction.Additionally,liver function abnormalities were noted in patients with severe COVID-19.Profound cytokine storm,direct viral infection,drugs and reactivation of viral infections were causes of deranged liver functions.Here,we discuss the relation between COVID-19 and chronic liver disease,specifically cirrhosis,hepatitis B,hepatitis C,and non-alcoholic fatty liver disease(NAFLD),as well as the liver manifestations of COVID-19.The metabolic syndrome,obesity,diabetes mellitus and NAFLD were found to worsen outcome in different studies reported worldwide.Decompensated cirrhosis should be considered a risk factor for death and severe COVID-19.Recently,COVID-19 related cholangiopathy has also been reported with changes of secondary sclerosing cholangitis.The long-term persistence of viral antigens in gut epithelia raises concern regarding the future risk of autoimmune liver diseases.

关 键 词：COVID-19 Chronic liver disease CIRRHOSIS Liver injury TRANSAMINASES Non-alcoholic fatty liver disease Post-acute COVID-19 syndrome 

分 类 号：R563.1[医药卫生—呼吸系统] R575[医药卫生—内科学]